Investigating how microglia and a specific receptor affect pain in multiple sclerosis.
Microglia and S1PR1 Signaling in Multiple Sclerosis Associated Neuropathic Pain
This study is looking at how certain brain cells might be causing pain in people with multiple sclerosis and testing a medication called fingolimod to see if it can help reduce that pain.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10904935 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms behind neuropathic pain experienced by individuals with multiple sclerosis (MS). It examines the role of microglia, a type of immune cell in the brain, and how their activation contributes to pain symptoms. The study utilizes a mouse model to explore the effects of a drug called fingolimod, which is already approved for MS treatment, to see how it interacts with specific receptors to alleviate pain. By uncovering these mechanisms, the research aims to identify new therapeutic targets for managing pain in MS patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple sclerosis who experience neuropathic pain.
Not a fit: Patients without multiple sclerosis or those who do not experience neuropathic pain may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for neuropathic pain in patients with multiple sclerosis.
How similar studies have performed: Previous studies have shown promising results in understanding pain mechanisms in other conditions, suggesting potential for success in this area as well.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Lamerand, Sydney — University of Pittsburgh at Pittsburgh
- Study coordinator: Lamerand, Sydney
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.